Sam Fazeli

speaker

906 appearances 5 recordings 1 series first heard Oct 2025 last heard 31 Mar

Sam Fazeli’s voice in public audio — every appearance, attributed to the second.

Trend

recordings per month · last 12 months

Recordings per month over the last 12 months — 5 in all, peaking in Mar 2026 with 2.

Appearances

newest first · ▶ plays the moment

Vanguards of Healthcare by Bloomberg Intelligence · Recapping ESMO, Inside AstraZeneca’s Bold Bet on Antibody Drug Conjugates · 27 Oct 2025 podcast

And that's, of course, the data they presented in breast cancer.

Now, just for setting the scene, because we have a whole variety of folks who listen to this podcast, from super experts to more generalists, just to be setting the scene here, breast cancer comes in

I would say, if that's fair enough, Susan, I don't know whether you agree, three main forms.

Hormone receptor positive, HER2 positive, and then, of course, triple negative breast cancer.

Do you agree with that?

Okay.

So you had some very interesting and exciting data at ESMO in the HER2 positive space.

And these are patients who have an alteration in either the expression or mutations in their HER2 gene, which whoever wants to can go on Google and find out about it.

So you had Destiny Breast 11 and Destiny Breast 05, both testing in two different settings.

And HER2, which is the HER2 ADC that you have as partnered with Daiichi Sankyo.

So maybe you want to talk us through that.

You have a big segment of this population in terms of patients covered.

Looking also at Destiny Bristol 9, Destiny Bristol 3, it begins to cover a whole population almost of the patients.

So do you want to tell us what we learned from DB11, just to shorten it, and what it means first for the DB11 and what it means for patients?

Now, these are patients, as you rightly say, that are being treated with curative intent.

Given that, how long do you think we'd have to wait to see if there's an impact on overall survival?

You did say that pathologic complete response, which just to be clear, is when you take tumors out and have a look at them and you find no viable cells.

There might be tumor there, but...

or at least a mass there, but no viable cells or very few.

How long would it take before we see whether there is a major or meaningful impact on survival here, which of course has to be the end game, right?

Showing 721–740 of 906 · page 37 of 46